Trickle Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (557)	4/19/2001 5:06:26 PM
From: nigel bates	Read Replies (1) of 1784

Wilder, from tuck's article - “We hope to get into the synthesis and design of third-generation Topo-I in-hibitors within 3 months,” says Stewart. “We will combine features of different classes of compounds to make completely novel inhibitors, which is nice from a patenting point of view. Then we hope to bring this work to a pharmaceutical company by the end of this year--that’s the power of crystallography.”... Speculative, definitely. As you say, though, 40 structures (for current state of the art) is pretty good going... Back too late..but I'm used to that Know the feeling well. nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next